指导类风湿关节炎患者治疗决策的不良预后因素：来自随机临床试验和队列研究的数据综述
Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.
作者信息
Albrecht Katinka, Zink Angela
机构信息
German Rheumatism Research Centre, Epidemiology Unit, Charitéplatz 1, 10117, Berlin, Germany.
Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany.
出版信息
Arthritis Res Ther. 2017 Mar 23;19(1):68. doi: 10.1186/s13075-017-1266-4.
Abstract
Prognostic factors are used for treatment decisions in rheumatoid arthritis (RA). High disease activity, the early presence of erosions, and autoantibody positivity are the most frequently used poor prognostic factors but other features, such as functional disability, extraarticular disease, or multibiomarkers, are also assessed. Prognostic factors are incorporated in current treatment recommendations for the management of RA and are used as inclusion criteria in randomized controlled trials. They are defined heterogeneously and the relevance of a single or combined presence of poor prognostic factors remains unclear. This review summarizes the current definitions of poor prognostic factors and their use in clinical research. Perspectives on future research are also outlined.
摘要
预后因素用于类风湿关节炎（RA）的治疗决策。高疾病活动度、早期出现侵蚀以及自身抗体阳性是最常用的不良预后因素，但其他特征，如功能残疾、关节外疾病或多种生物标志物也会被评估。预后因素已纳入当前RA管理的治疗建议中，并用作随机对照试验的纳入标准。它们的定义并不统一，单一或合并存在不良预后因素的相关性仍不明确。本综述总结了不良预后因素的当前定义及其在临床研究中的应用。还概述了未来研究的展望。
相似文献
1
Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies.指导类风湿关节炎患者治疗决策的不良预后因素：来自随机临床试验和队列研究的数据综述
Arthritis Res Ther. 2017 Mar 23;19(1):68. doi: 10.1186/s13075-017-1266-4.
2
Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.预后因素是否能充分选择以指导类风湿关节炎患者的治疗决策？来自三个观察队列的协作分析。
Semin Arthritis Rheum. 2019 Jun;48(6):976-982. doi: 10.1016/j.semarthrit.2018.09.003. Epub 2018 Sep 17.
3
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.早期血清阴性类风湿关节炎中对常规合成 DMARDs 反应良好的预测因素：来自 ESPOIR 队列的数据。
Arthritis Res Ther. 2019 Nov 15;21(1):243. doi: 10.1186/s13075-019-2020-x.
4
Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey.预后因素对类风湿关节炎靶向治疗处方的影响：德尔菲调查。
Joint Bone Spine. 2021 Jul;88(4):105172. doi: 10.1016/j.jbspin.2021.105172. Epub 2021 Mar 6.
5
Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.类风湿关节炎预后不良因素是否会影响治疗选择和结局？美国类风湿关节炎注册研究分析。
J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1.
6
Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands.25 年以上自身抗体阳性和阴性类风湿关节炎患者的强化治疗策略和不同疾病结局：荷兰的一项纵向队列研究。
PLoS Med. 2020 Sep 22;17(9):e1003296. doi: 10.1371/journal.pmed.1003296. eCollection 2020 Sep.
7
Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews.评估早期类风湿关节炎的预后和治疗反应预测：系统评价。
Health Technol Assess. 2018 Nov;22(66):1-294. doi: 10.3310/hta22660.
8
[Are useful prognostic factors in rheumatoid arthritis?].[类风湿关节炎中有用的预后因素？]
Reumatol Clin. 2011 Sep-Oct;7(5):339-42. doi: 10.1016/j.reuma.2010.11.006. Epub 2011 Feb 26.
9
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide.新诊断类风湿关节炎的早期转诊建议：基于证据制定临床指南
Ann Rheum Dis. 2002 Apr;61(4):290-7. doi: 10.1136/ard.61.4.290.
10
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.在未使用甲氨蝶呤且预后因素较差的早期类风湿性关节炎患者中开展的第一项关于赛妥珠单抗聚乙二醇化修饰物的双盲、随机、平行组研究——C-OPERA研究，显示出对影像学进展的抑制作用。
Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.
引用本文的文献
1
Triple positivity for autoantibodies in patients with rheumatoid arthritis is associated with a severe course of the disease but not with bone turnover markers.类风湿关节炎患者自身抗体三联阳性与疾病的严重病程相关，但与骨转换标志物无关。
Reumatologia. 2025 Apr 30;63(2):81-88. doi: 10.5114/reum/200527. eCollection 2025.
2
Transitional and CD21 PD-1 B cells are associated with remission in early rheumatoid arthritis.过渡性和CD21 PD-1 B细胞与早期类风湿关节炎的缓解相关。
BMC Rheumatol. 2025 Apr 21;9(1):45. doi: 10.1186/s41927-025-00487-x.
3
Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis.类风湿因子：类风湿关节炎的诊断、预后评估及治疗意义
J Clin Med. 2025 Feb 25;14(5):1529. doi: 10.3390/jcm14051529.
4
Metabolomics for Distinguishing Cardiovascular Risk in Rheumatoid Arthritis Across Different Disease-Modifying Antirheumatic Drug Therapies.代谢组学用于区分类风湿关节炎中不同改善病情抗风湿药物治疗下的心血管风险
J Clin Med Res. 2025 Feb;17(2):89-96. doi: 10.14740/jocmr6145. Epub 2025 Feb 13.
5
Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update.《中国类风湿关节炎诊疗指南（2024年版）》
Rheumatol Immunol Res. 2025 Jan 9;5(4):189-208. doi: 10.1515/rir-2024-0028. eCollection 2024 Dec.
6
Yoga as an adjunctive therapy for rheumatoid arthritis.瑜伽作为类风湿性关节炎的辅助疗法。
Cochrane Database Syst Rev. 2025 Jan 7;1(1):CD015300. doi: 10.1002/14651858.CD015300.
7
High-Titer Rheumatoid Factor is Associated with Worse Clinical Outcomes and Higher Needs for Advanced Therapies in Rheumatoid Arthritis Under Real-Life Conditions.在现实生活条件下，高滴度类风湿因子与类风湿关节炎更差的临床结局及对先进治疗的更高需求相关。
Rheumatol Ther. 2025 Feb;12(1):123-136. doi: 10.1007/s40744-024-00730-w. Epub 2024 Dec 19.
8
On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis.关于类风湿关节炎临床实践中预后因素定义的困难。
RMD Open. 2024 Sep 28;10(3):e004472. doi: 10.1136/rmdopen-2024-004472.
9
Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: a cohort study.在一家国家级转诊中心，类风湿关节炎患者甲氨蝶呤单药治疗成功的预测因素：一项队列研究
BMC Rheumatol. 2024 Sep 12;8(1):42. doi: 10.1186/s41927-024-00412-8.
10
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.类风湿因子水平高对类风湿关节炎患者接受培塞丽珠单抗和阿达木单抗治疗结局的影响。
Rheumatology (Oxford). 2024 Nov 1;63(11):3015-3024. doi: 10.1093/rheumatology/keae435.
本文引用的文献
1
Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.初治类风湿关节炎年轻与老年患者使用阿巴西普实现持续临床缓解的预测因素差异：ABROAD研究结果
J Rheumatol. 2016 Nov;43(11):1974-1983. doi: 10.3899/jrheum.160051. Epub 2016 Sep 1.
2
Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.尽管接受甲氨蝶呤治疗，但仍发生快速放射学进展的早期类风湿关节炎患者的识别用基质的表现：基于 ESPOIR 队列数据的外部验证研究。
RMD Open. 2016 May 20;2(1):e000245. doi: 10.1136/rmdopen-2016-000245. eCollection 2016.
3
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.在未使用过改善病情抗风湿药（DMARD）、具有不良预后因素的早期、活动期类风湿关节炎患者中，聚乙二醇化赛妥珠单抗联合剂量优化的甲氨蝶呤的疗效：来自随机、双盲、安慰剂对照III期研究C-EARLY的1年结果
Ann Rheum Dis. 2017 Jan;76(1):96-104. doi: 10.1136/annrheumdis-2015-209057. Epub 2016 May 10.
4
Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy.临床实践中类风湿关节炎患者出现具有临床意义的影像学进展的预后因素：一项日本多中心前瞻性纵向队列研究，以实现达标治疗策略
Medicine (Baltimore). 2016 Apr;95(17):e3476. doi: 10.1097/MD.0000000000003476.
5
Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES.即使在抗环瓜氨酸肽抗体（ACPA）阴性的早期类风湿性关节炎中，我们也需要应用从诊断到治疗（T2T）策略吗？答案是肯定的。
RMD Open. 2016 Mar 25;2(1):e000263. doi: 10.1136/rmdopen-2016-000263. eCollection 2016.
6
Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.通过RAPID3和其他核心数据集指标预测法国早期关节炎队列中的病情缓解情况，而非通过类风湿因子、抗瓜氨酸化蛋白抗体或影像学侵蚀的缺失情况进行预测。
J Rheumatol. 2016 Jul;43(7):1285-91. doi: 10.3899/jrheum.141586. Epub 2016 Apr 15.
7
Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.多时间点多生物标志物疾病活动评分与类风湿关节炎放射学进展的相关性：来自 SWEFOT 试验的结果。
RMD Open. 2016 Mar 1;2(1):e000197. doi: 10.1136/rmdopen-2015-000197. eCollection 2016.
8
Biomarkers to guide clinical therapeutics in rheumatology?用于指导风湿病临床治疗的生物标志物？
Curr Opin Rheumatol. 2016 Mar;28(2):168-75. doi: 10.1097/BOR.0000000000000250.
9
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.2015 年美国风湿病学会类风湿关节炎治疗指南。
Arthritis Rheumatol. 2016 Jan;68(1):1-26. doi: 10.1002/art.39480. Epub 2015 Nov 6.
10
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.托珠单抗治疗早期进展性类风湿关节炎：FUNCTION随机对照试验
Ann Rheum Dis. 2016 Jun;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628. Epub 2015 Oct 28.
Zotero 插件